FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD), today announced a refined clinical development strategy focused on advancing its most mature drug candidates to New Drug Applications (NDAs) with the Food and Drug Administration (FDA). NovaDel’s pipeline includes late-stage drug candidates Zolpidem Oral Spray for insomnia and Sumatriptan Oral Spray for migraine. NovaDel recently announced positive pivotal data on Zolpidem Oral Spray, and plans to submit the New Drug Application (NDA) for this product to the Food and Drug Administration (FDA) during the second half of 2007.
